BioXcel Therapeutics Announces Updated Presentation Time at H.C. Wainwright Global Investment Conference
20 mai 2022 07h00 HE
|
BioXcel Therapeutics
NEW HAVEN, Conn., May 20, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop...
BioXcel Therapeutics Reports First Quarter 2022 Financial Results and Recent Operational Highlights
09 mai 2022 07h00 HE
|
BioXcel Therapeutics
Received FDA approval of IGALMI™ (dexmedetomidine) sublingual film for acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults Top-line data readout in Q4...
BioXcel Therapeutics to Present at Three Upcoming Investor Conferences
05 mai 2022 07h00 HE
|
BioXcel Therapeutics
NEW HAVEN, Conn., May 05, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop...
BioXcel Therapeutics Announces First Patient Dosed in TRANQUILITY II Phase 3 Trial for Acute Treatment of Agitation in Patients with Alzheimer’s Disease
03 mai 2022 07h00 HE
|
BioXcel Therapeutics
Top-line data for TRANQUILITY II anticipated in Q4 2022/early Q1 2023 Phase 3 TRANQUILITY III study underway with patient enrollment initiating in H2 2022 NEW HAVEN, Conn., May 03, 2022 (GLOBE...
BioXcel Therapeutics to Report First Quarter 2022 Financial Results on May 9, 2022
26 avr. 2022 07h00 HE
|
BioXcel Therapeutics
NEW HAVEN, Conn., April 26, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelligence (AI) approaches to...
BioXcel Therapeutics Announces Formation of OnkosXcel Therapeutics to Develop Medicines Focused in Oncology
19 avr. 2022 07h05 HE
|
BioXcel Therapeutics
OnkosXcel, a Company subsidiary, to utilize proprietary AI-powered platform to progress therapies to address difficult-to-treat cancers with high unmet need New structure to unlock growth...
BioXcel Therapeutics Announces $260 Million Strategic Financing with Oaktree and Qatar Investment Authority
19 avr. 2022 07h00 HE
|
BioXcel Therapeutics
Investment will support upcoming U.S. commercial launch activities of IGALMI™ and further clinical pipeline development Extends Company’s cash runway into 2025 NEW HAVEN, Conn., April 19, 2022 ...
BioXcel Therapeutics Announces FDA Approval of IGALMI™ (dexmedetomidine) Sublingual Film for Acute Treatment of Agitation Associated with Schizophrenia or Bipolar I or II Disorder in Adults
06 avr. 2022 07h00 HE
|
BioXcel Therapeutics
First and only FDA-approved orally dissolving sublingual film for mild, moderate or severe agitation in patients with schizophrenia or bipolar I or II disorder1 IGALMI demonstrated onset of...
BioXcel Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Operational Highlights
10 mars 2022 07h05 HE
|
BioXcel Therapeutics
Ready to launch BXCL501 upon approval as Company nears April 5, 2022 PDUFA action date Initiated TRANQUILITY II AND III pivotal Phase 3 trials for BXCL501 in acute treatment of agitation associated...
BioXcel Therapeutics to Present at the Barclays Global Healthcare Conference
09 mars 2022 07h00 HE
|
BioXcel Therapeutics
NEW HAVEN, Conn., March 09, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop...